Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs D R Horton Inc (DHI) Price & Performance

Abeona Therapeutics IncTrade
D R Horton IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs D R Horton Inc — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while D R Horton Inc trades at $146.43 (market cap $42.18B). The key difference: D R Horton Inc is far larger — about 100.1× Abeona Therapeutics Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEODHI
Market Cap
$421.19M$42.18B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$184.04
52-Week Low
$4.17$132.53
Enterprise Value
$276.10M$47.28B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

D R Horton Inc

D.R. Horton (DHI) trades at $146.44, down slightly by 0.15% today, with a bullish technical signal from moving averages. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance due to soft demand. Valuation metrics appear reasonable with a P/E of 14.37 and P/S of 1.31, while profitability margins have compressed over recent years.

The outlook is mixed: strong cash flow and execution support the stock, but elevated mortgage rates and weak homebuying trends pose headwinds. Analyst consensus is a Buy with a $153 price target, indicating modest upside potential, though risks from housing market volatility persist.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About D R Horton Inc

D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.

Read more on DHI